Literature DB >> 25005329

A systematic review of bone mineral density and fractures in phenylketonuria.

Karen E Hansen1, Denise Ney.   

Abstract

INTRODUCTION: Our objective was to systematically review and analyze published data on bone mineral density (BMD) and fracture rates in patients with phenylketonuria (PKU), and relationships between BMD and phenylalanine levels.
METHODOLOGY: We searched PubMed, CINAHL, and Cochrane databases from January 1966 to November 2013 for studies of spine BMD or fracture in PKU and control subjects. We excluded studies assessing skeletal health by ultrasound or peripheral quantitative computer tomography. Both authors reviewed abstracts for inclusion, and read full text papers to extract data.
RESULTS: Sixteen studies met eligibility criteria. Meta-analysis of three studies found that spine BMD was 0.100 g/cm(2) lower (95% CI, -0.110, -0.090 g/cm(2)) in 67 subjects with PKU, compared to 161 controls. Among six studies, 20% (53 of 263) of PKU subjects experienced clinical fractures. In the single study with controls, the fracture rate was 2.6 fold higher (95% CI, 1.1-6.1) after age 8 in PKU subjects, compared to healthy sibling controls. When considering a total of 12 studies in 412 subjects, nine or 75% of studies representing 71% of studied subjects reported no association between phenylalanine levels and BMD. Spine BMD is lower in PKU than control subjects, but only one study controlled for smaller body size. Existing studies suggest a clinical fracture rate of 20% among PKU subjects, but fracture rates in controls are lacking. Finally, existing data shows no consistent relationship between phenylalanine levels and BMD. Future studies are needed to clarify the etiology and health consequences of low BMD in PKU.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25005329      PMCID: PMC4208974          DOI: 10.1007/s10545-014-9735-2

Source DB:  PubMed          Journal:  J Inherit Metab Dis        ISSN: 0141-8955            Impact factor:   4.982


  23 in total

Review 1.  Measuring inconsistency in meta-analyses.

Authors:  Julian P T Higgins; Simon G Thompson; Jonathan J Deeks; Douglas G Altman
Journal:  BMJ       Date:  2003-09-06

2.  Influence of phenylalanine intake on phenylketonuria.

Authors:  H BICKEL; J GERRARD; E M HICKMANS
Journal:  Lancet       Date:  1953-10-17       Impact factor: 79.321

3.  Dual energy X-ray absorptiometry interpretation and reporting in children and adolescents: the 2007 ISCD Pediatric Official Positions.

Authors:  Catherine M Gordon; Laura K Bachrach; Thomas O Carpenter; Nicola Crabtree; Ghada El-Hajj Fuleihan; Stepan Kutilek; Roman S Lorenc; Laura L Tosi; Katherine A Ward; Leanne M Ward; Heidi J Kalkwarf
Journal:  J Clin Densitom       Date:  2008 Jan-Mar       Impact factor: 2.617

4.  Is deoxypyridinoline a good resorption marker to detect osteopenia in phenylketonuria?

Authors:  Pablo Millet; M Antonia Vilaseca; Carme Valls; Belén Pérez-Dueñas; Rafael Artuch; Lilian Gómez; Nilo Lambruschini; Jaume Campistol
Journal:  Clin Biochem       Date:  2005-10-27       Impact factor: 3.281

5.  Bone metabolism and the muscle-bone relationship in children, adolescents and young adults with phenylketonuria.

Authors:  Piotr Adamczyk; Aurelia Morawiec-Knysak; Paweł Płudowski; Beata Banaszak; Jacek Karpe; Wojciech Pluskiewicz
Journal:  J Bone Miner Metab       Date:  2010-08-13       Impact factor: 2.626

Review 6.  National Institutes of Health Consensus Development Conference Statement: phenylketonuria: screening and management, October 16-18, 2000.

Authors: 
Journal:  Pediatrics       Date:  2001-10       Impact factor: 7.124

7.  New approach to osteopenia in phenylketonuric patients.

Authors:  B Pérez-Dueñas; F J Cambra; M A Vilaseca; N Lambruschini; J Campistol; J A Camacho
Journal:  Acta Paediatr       Date:  2002       Impact factor: 2.299

8.  Decreased bone mineralization in children with phenylketonuria under treatment.

Authors:  L Hillman; C Schlotzhauer; D Lee; J Grasela; S Witter; S Allen; R Hillman
Journal:  Eur J Pediatr       Date:  1996-07       Impact factor: 3.183

9.  Bone mineral status in children with phenylketonuria under treatment.

Authors:  A Al-Qadreh; K H Schulpis; H Athanasopoulou; C Mengreli; A Skarpalezou; I Voskaki
Journal:  Acta Paediatr       Date:  1998-11       Impact factor: 2.299

10.  Peak bone mass in patients with phenylketonuria.

Authors:  D Modan-Moses; I Vered; G Schwartz; Y Anikster; S Abraham; R Segev; Ori Efrati
Journal:  J Inherit Metab Dis       Date:  2007-03-08       Impact factor: 4.750

View more
  13 in total

1.  Analysis of the functional muscle-bone unit of the forearm in patients with phenylketonuria by peripheral quantitative computed tomography.

Authors:  Daniela Choukair; Carolin Kneppo; Reinhard Feneberg; Eckhard Schönau; Martin Lindner; Stefan Kölker; Georg F Hoffmann; Burkhard Tönshoff
Journal:  J Inherit Metab Dis       Date:  2016-11-22       Impact factor: 4.982

2.  Impact of Dietary Intake on Bone Turnover in Patients with Phenylalanine Hydroxylase Deficiency.

Authors:  Kathryn E Coakley; Eric I Felner; Vin Tangpricha; Peter W F Wilson; Rani H Singh
Journal:  JIMD Rep       Date:  2017-01-28

3.  A New View of Bone Loss in Phenylketonuria.

Authors:  Steven F Dobrowolski; Irina L Tourkova; Cayla R Sudano; Quitterie C Larrouture; Harry C Blair
Journal:  Organogenesis       Date:  2021-08-25       Impact factor: 2.316

4.  Glycomacropeptide is a prebiotic that reduces Desulfovibrio bacteria, increases cecal short-chain fatty acids, and is anti-inflammatory in mice.

Authors:  Emily A Sawin; Travis J De Wolfe; Busra Aktas; Bridget M Stroup; Sangita G Murali; James L Steele; Denise M Ney
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2015-08-06       Impact factor: 4.052

Review 5.  The complete European guidelines on phenylketonuria: diagnosis and treatment.

Authors:  A M J van Wegberg; A MacDonald; K Ahring; A Bélanger-Quintana; N Blau; A M Bosch; A Burlina; J Campistol; F Feillet; M Giżewska; S C Huijbregts; S Kearney; V Leuzzi; F Maillot; A C Muntau; M van Rijn; F Trefz; J H Walter; F J van Spronsen
Journal:  Orphanet J Rare Dis       Date:  2017-10-12       Impact factor: 4.123

Review 6.  Bone health in phenylketonuria: a systematic review and meta-analysis.

Authors:  Serwet Demirdas; Katie E Coakley; Peter H Bisschop; Carla E M Hollak; Annet M Bosch; Rani H Singh
Journal:  Orphanet J Rare Dis       Date:  2015-02-15       Impact factor: 4.123

7.  Glycomacropeptide for nutritional management of phenylketonuria: a randomized, controlled, crossover trial.

Authors:  Denise M Ney; Bridget M Stroup; Murray K Clayton; Sangita G Murali; Gregory M Rice; Frances Rohr; Harvey L Levy
Journal:  Am J Clin Nutr       Date:  2016-07-13       Impact factor: 7.045

8.  Amino Acid Medical Foods Provide a High Dietary Acid Load and Increase Urinary Excretion of Renal Net Acid, Calcium, and Magnesium Compared with Glycomacropeptide Medical Foods in Phenylketonuria.

Authors:  Bridget M Stroup; Emily A Sawin; Sangita G Murali; Neil Binkley; Karen E Hansen; Denise M Ney
Journal:  J Nutr Metab       Date:  2017-05-04

Review 9.  Bone health in patients with inborn errors of metabolism.

Authors:  M Langeveld; C E M Hollak
Journal:  Rev Endocr Metab Disord       Date:  2018-03       Impact factor: 6.514

10.  Sex differences in body composition and bone mineral density in phenylketonuria: A cross-sectional study.

Authors:  Bridget M Stroup; Karen E Hansen; Diane Krueger; Neil Binkley; Denise M Ney
Journal:  Mol Genet Metab Rep       Date:  2018-02-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.